Now That You Have Been Diagnosed with Breast Cancer, Learn How The

AdvantagesAdvantages of SYMPHONY of SYMPHONY breast breast cancer cancer pro le: pro le:

• The• mostThe most comprehensive comprehensive information information about about your your cancer cancer NNowow that that you you type,type, which which is vital is vitalfor making for making decisions decisions about about your your treatment. treatment. havehave been been • Definitive• Definitive result result in 100% in 100% of cases. of cases. No Intermediate No Intermediate results. results. diagnoseddiagnosed with with • It can• It becan done be done at any at pointany point during during your your treatment treatment planning. planning. breastbreast cancer, cancer, • Only• Only test oftest its of kind its kindcleared cleared by the by U.S.the U.S.FDA. FDA. learnlearn how how the the • Provides• Provides risk ofrisk recurrence, of recurrence, potential potential response response to to SYMPHONYTM TM chemotherapy,chemotherapy, and determinesand determines if targeted if targeted therapy therapy is right is right for for SYMPHONY you.you. personalizedpersonalized genomicgenomic breast breast cancercancer pro le pro le cancan help help you you taketake the the nextnext step. step.

M-USA-002-V1 No two tumors are alike….

Why should they be treated the same? No Notwo two tumors tumors are are alike…. alike…. With today’s medicine we now have technology available that WhyWhy should should they they be betreated treated the the same? same? can determine the biology of your speci c tumor type. This information, called a genomic pro le, is used to tailor your WithWith today’s today’s medicine medicine we wenow now have have technology technology available available that that cancer treatment plan around your speci c tumor biology to cancan determine determine the the biology biology of yourof your speci c speci c tumor tumor type. type. This This give you the best outcome with the fewest side effects. information,information, called called a genomic a genomic pro le, pro le, is used is used to tailorto tailor your your cancercancer treatment treatment plan plan around around your your speci c speci c tumor tumor biology biology to to Matching an individual’s biology with a selected therapy is givegive you you the the best best outcome outcome with with the the fewest fewest side side effects. effects. called personalized medicine. Looking at the genes in your tumor and determining how the genes are functioning is the MatchingMatching an anindividual’s individual’s biology biology with with a selected a selected therapy therapy is is rst step in personalizing your medical plan. Once the calledcalled personalized personalized medicine. medicine. Looking Looking at theat the genes genes in yourin your genomic test has been performed, that information will tell tumortumor and and determining determining how how the the genes genes are are functioning functioning is the is the you and your doctor how your tumor is behaving and to which rst rst step step in personalizingin personalizing your your medical medical plan. plan. Once Once the the therapy it will best respond. genomicgenomic test test has has been been performed, performed, that that information information will will tell tell youyou and and your your doctor doctor how how your your tumor tumor is behaving is behaving and and to whichto which Your doctor thinks that the Symphony personalized breast therapytherapy it will it will best best respond. respond. cancer genomic pro le will help guide your treatment plan, which is why you were given this brochure. YourYour doctor doctor thinks thinks that that the the Symphony Symphony personalized personalized breast breast cancercancer genomic genomic pro le pro le will will help help guide guide your your treatment treatment plan, plan, whichwhich is why is why you you were were given given this this brochure. brochure.

MammaPrintMammaPrint MammaPrint ClearedCleared by byCleared by Oprah Winfrey recognized Dr. Laura van ’t Veer, Co-founder of Agendia, for her work on MammaPrint as one of the “Five Biggest FDAUS Food andFDAUS Drug Food Administration and Drug AdministrationFDAUS Food and Drug Administration Health Breakthroughs by Women Scientists” in “0” Magazine Silver Springs,Silver MD Springs, 20993 MD 20993Silver Springs, MD 20993

TIME Magazine chose MammaPrint as one of the “Five Best Healthcare Inventions of the Year” naming it “Cancer’s Crystal Ball.”

10 10 1 1 Personalized Medicine:

Personalized medicine for your breast cancer begins with Symphony genomic breast SYMPHONY is the most cancer pro le. This is a suite of four genomic tests that will provide comprehensive genomic pro le that information speci c to your tumor about how aggressive it is behaving can de nitively tell you the and which molecular pathways are driving its growth. This knowledge, probability of recurrence and coupled with your own medical history and clinical pathology, will help responsiveness to chemotherapy determine which treatment plan is best for YOU. based on your molecular subtype. It will help determine if you will bene t from chemotherapy, hormonal therapy, or other combinations of treatments.

The SYMPHONY genomic pro le will guide your treatment decisions and help answer the following questions:

• Will you benefit from chemotherapy? • Based on your molecular subtype, are there specific combinations of therapy that will be more selective in treating your type of cancer? • Will your tumor respond to hormonal therapy? • Are there alternate therapy options if your tumor does not respond?

9 2 WhatWhat is the is theSYMPHONY SYMPHONY personalized personalized WillWill my myinsurance insurance cover cover the thecost cost of SYMPHONY? of SYMPHONY? breastbreast cancer cancer Pro le? Pro le? AgendiaAgendia bills billsinsurance insurance companies companies on behalf on behalf of insured of insured patients patients throughout throughout the Unitedthe United The TheSYMPHONY SYMPHONY personalized personalized genomic genomic pro le pro le for breast for breast States.States. Based Based on the on patient’sthe patient’s speci c speci c bene t bene t level, level, the insurancethe insurance companies companies may maypay apay a portion or all of the cost of the Symphony tests. cancercancer began began as one as onetest, test,MammaPrint MammaPrint®. It® . It portion or all of the cost of the Symphony tests. nownow includes includes 4 tests, 4 tests, MammaPrint, MammaPrint, BluePrint BluePrintTM, TM, TargetPrintTargetPrint®, and®, andTheraPrint TheraPrint®. Each®. Each of these of these tests tests WhatWhat if I don’tif I don’t have have insurance insurance or my or myinsurance insurance doesn’t doesn’t cover cover it? it? lookslooks at different at different gene gene sets setsin your in your tumor tumor and andprovides provides in-depthin-depth information information about about speci c speci c tumor tumor AgendiaAgendia is a compassionateis a compassionate company company offering offering a wide a wide range range of nancial of nancial assistance assistance characteristics.characteristics. Your Your tumor tumor characteristics characteristics will helpwill help programs.programs. Please Please contact contact Agendia’s Agendia’s billing billing department department at 888-363-7868 at 888-363-7868 or or [email protected]@agendia.com. directdirect your your personal personal treatment treatment plan. plan.

WhereWhere can can I nd I nd more more information information about about breast breast cancer cancer and and the the MammaPrintMammaPrint studies studies 70 prognostic 70 prognostic genes genes SYMPHONYSYMPHONY genomic genomic pro le? pro le? that thatdetermine determine your your risk ofrisk recurrence. of recurrence. You You will receivewill receive a de nitive a de nitive result: result: Low LowRisk Riskor or For moreFor more information information please please visit visitwww.know www.knowYOURYOURbreastcancer.combreastcancer.com or or HighHigh Risk. Risk. There There are noare intermediate no intermediate results results scanscan the barcodethe barcode below below with with your your smartphone. smartphone. that thatmay maylead leadto further to further indecision. indecision. Results Results are givenare given based based on what on what would would happen happen if if you youhad hadno treatment no treatment at all. at Your all. Your test test resultsresults will comewill come back back as having as having either either a High a High Risk Riskor Low or LowRisk Riskof recurrence. of recurrence.

If youIf youare inare the in Lowthe LowRisk Riskcategory, category, you youhave have a 10% a 10% chance chance of your of your cancer cancer returning returning withinwithin 10 years 10 years after after surgery surgery with with no adjuvant no adjuvant hormon hormonal oral chemotherapy. or chemotherapy. There There is is little,little, if any, if any,bene t bene t to getting to getting chemotherapy. chemotherapy. By adding By adding hormonal hormonal therapy therapy alone alone your your risk canrisk becan lowered be lowered to about to about 5% chance5% chance of recurrence. of recurrence.

If youIf youare inare the in Highthe High Risk Riskcategory, category, you youhave have a 29% a 29% chance chance of your of your cancer cancer returning returning withinwithin the nextthe next 10 years 10 years and andyou youshould should consider consider chemotherapy chemotherapy as part as partof your of your regimen.regimen. High High Risk Riskpatients patients can becan separated be separated into intosubtypes, subtypes, which which can furthercan further re ne re ne youryour treatment treatment plan. plan.

3 3 8 8 WhatWhat should should I do Ito do have to have the SYMPHONYthe SYMPHONY breast breast cancer cancer BluePrintBluePrint investigates investigates 80 genes 80 genes that identifythat identify the molecular the molecular subtype subtype of your of your genomicgenomic pro le pro le ordered ordered for me? for me? tumortumor so that so youthat and you yourand yourdoctor doctor can choose can choose the drug the drugcombination combination that offersthat offers the bestthe therapeuticbest therapeutic result result for your for yourspeci c speci c tumor tumor type. type. There There are four are mainfour main DuringDuring your yourpreliminary preliminary consultation, consultation, ask your ask yourdoctor doctor to order to order subtypes:subtypes: HER2 HER2 (also (alsocalled called ERBB2), ERBB2), basal, basal, luminal luminal A and A luminaland luminal B. Each B. Eachof these of these the SYMPHONYthe SYMPHONY suite suiteof tests of testsso that so youthat can you make can make more more molecularmolecular subtypes subtypes respond respond differently differently to various to various therapies. therapies. By knowing By knowing your your informedinformed decisions decisions about about treatment treatment options options for you. for you. subtype,subtype, your yourdoctor doctor can select can select the most the mosteffective effective treatment treatment for your for yourtype oftype of cancer.cancer.

WhereWhere are theare SYMPHONYthe SYMPHONY tests tests performed? performed? TargetPrintTargetPrint quanti es quanti es ER, PR, ER, HER2 PR, HER2 receptor receptor status status by measuring by measuring mRNA mRNA to more to more The testsThe testsare performed are performed in state-of-the-art in state-of-the-art Clinical Clinical preciselyprecisely determine determine your yourreceptor receptor status. status. Research Research has shown has shown that mRNAthat mRNA LaboratoryLaboratory Improvement Improvement Amendments Amendments (CLIA) (CLIA) and theand the measurementmeasurement of these of these receptors receptors are linked are linked to improved to improved outcomes outcomes over traditionalover traditional CollegeCollege of Pathology of Pathology (CAP) (CAP) certi ed, certi ed, registered, registered, and and stainingstaining methods methods for these for these receptors. receptors. Your Yourreceptor receptor status status will determine will determine if your if your compliantcompliant genomics genomics laboratories laboratories in Irvine, in Irvine, California, California, USA andUSA inand Amsterdam, in Amsterdam, The The tumortumor will respond will respond to targeted to targeted therapy. therapy. Netherlands.Netherlands. TheraPrintTheraPrint looks looksat 56 at genes 56 genes that canthat help can determinehelp determine an alternate an alternate course course of of HowHow long long will itwill take it taketo get to myget SYMPHONYmy SYMPHONY results? results? therapy,therapy, if necessary. if necessary.

We understandWe understand the urgency the urgency of the of test the result test result and itsand impact its impact on treatment on treatment decisions. decisions. All of Allthese of these genomic genomic tests testscombined, combined, called called SYMPHONY, SYMPHONY, will provide will provide you and you and All testsAll testsare performed are performed with awith fast a turnaround fast turnaround time timewhile while maintaining maintaining the strictest the strictest your yourdoctor doctor with thewith most the mostcomprehensive comprehensive information information available available to help to guidehelp guide qualityquality control. control. The test The results test results are delivered are delivered to your to yourphysician physician approximately approximately 10 10 your yourdecision decision making making process process for treatment for treatment planning. planning. workingworking days daysafter afterthe sample the sample submission. submission.

7 7

4 4 How MammaPrint How MammaPrint was validated? was validated?

How wereHow the were genomic the genomic tests in tests SYMPHONY in SYMPHONY discovered? discovered? MammaPrint How MammaPrint MammaPrint How has MammaPrintbeen has validated beenwas validatedvalidated? in was independent validated? in independent studies studies in morein than more 6,000 than breast 6,000 cancer breast patientscancer patients at major at major AsHow published AswereHow published inthe wereNature, genomic inthe Nature,the genomic SYMPHONY tests the SYMPHONYin tests SYMPHONY genomic in SYMPHONY genomic pro le discovered? was pro le discovered?developed was developed by by MammaPrintcancerMammaPrint centerscancer has beencentersin Europe has validated beenin andEurope validated thein independentand U.S. the in The independent U.S. results studies The have results studies have taking samplestaking samples from a populationfrom a population of thousands of thousands untreated untreated breast cancer breast cancer in morebeen in publishedthan morebeen 6,000 publishedthan in breast prestigious6,000 incancer breast prestigious journals patientscancer journals with patients at major external with at major external tumorsAs published tumorswhoseAs published in 10 whoseNature, year in 10outcome Nature,the year SYMPHONY outcome the was SYMPHONY known. was genomic known.Using genomic pro le these Using wasuntreated pro le these developed wasuntreated breast developed by breast by cancerpeer centerscancerscienti cpeer centersinscienti c review,Europe in suchreview,andEurope theas suchNewand U.S. theas England The New U.S. results England TheJournal have results ofJournal have of takingcancer samplestumors,takingcancer samples tumors, fromthey lookeda population fromthey atlookeda populationall 25,000of at thousands all 25,000humanof thousands untreated humangenes untreatedin genes breastorder in to cancer breastorder learn to whichcancer learn which beenMedicine, publishedbeenMedicine, Lancetpublished in prestigious Oncology,Lancet in prestigious Oncology, journals Journal journals withofJournal the external National withof the external National tumorsones are tumorswhoseones involved are 10whose involved yearin breast 10outcome yearin cancer breast outcome was metastasis.cancer known. was metastasis. known.Using Researchers these Using Researchers untreated werethese ableuntreated were breast to separateable breast to separate the the peerCancer scienti cpeer CancerInstitute, scienti c review, Institute, Clinical suchreview, asClinicalCancer suchNew asEnglandCancerResearch New EnglandResearch Journal and Breast ofJournal and Breast of cancertumors tumors,cancer tumorsinto two tumors, theyinto categories: lookedtwo they categories: atlooked those all 25,000 tumorsat those all 25,000human tumorsthat came humangenes that back camein genes order and back inthose to order andlearn tumors those to which learn tumorsthat which did that did Medicine,CancerMedicine, CancerResearchLancet Oncology,ResearchLancet and Treatment Oncology, and Journal Treatment4-15 ofJournal. the4-15 National of. the National onesnot recurareones notinvolved within recurare involved 10 inwithin breastyears. 10in cancer Bybreastyears. comparing metastasis.cancer By comparing metastasis.the Researchersgene the expression Researchersgene were expression ofable werethe to two ofseparateable the groups to two separate the ofgroups the of Cancer CancerInstitute, Institute, Clinical ClinicalCancer CancerResearch Research and Breast and Breast tumorstumor tumorsintocells,tumor two they intocells, categories: were two they ablecategories: were those to identifyable tumors those to identifythe tumorsthat most came the prognosticthat most back came prognostic and backgenes those and involved genestumors those involved tumorsinthat breast did inthat breast did CancerTo date, CancerResearchTo more date, Research andthan more Treatment 30,000 andthan Treatment 30,000early4-15. stage early4-15 breast. stage cancer breast cancer notcancer. recurnot cancer. withinA recurprecise 10 withinA bioinformaticspreciseyears. 10 Bybioinformaticsyears. comparing algorithmBy comparing thealgorithm was gene usedthe expression was gene to useddetermine expression toof determinethe the two of 70the groups genethe two 70 ofgroups gene of patients,patients, like you, like have you, chosen have chosenSymphony Symphony to evaluate to evaluate tumorexpression cells,tumorexpression theysignature cells, were theysignature thatable were clearlyto identifythatable and clearlyto identify theaccurately andmost theaccurately prognostic identi edmost prognostic identi ed genesthose tumorsinvolved genesthose tumorsthatinvolved in breast would that in likelybreast would likely To theirdate, Toindividual more theirdate, than individual more risk 30,000 thanof recurrence. risk 30,000early of recurrence.stage early breast stage cancer breast cancer cancer.recur cancer.in A recur10precise years in A 10bioinformaticsprecise and years those bioinformatics and that those algorithm would that algorithm not would was1. used not was1 to. useddetermine to determine the 70 genethe 70 gene patients,patients, like you, like have you, chosen have chosenSymphony Symphony to evaluate to evaluate expressionexpression signature signature that clearly that andclearly accurately and accurately identi ed identi ed those tumors those tumorsthat would that likely would likely their individualtheir individual risk of recurrence. risk of recurrence. recurMammaPrint in recur10MammaPrint years in 10is and the years thoseonly is and the gene that thoseonly wouldexpression gene that not wouldexpression1 .pro le not 1cleared .pro le clearedby the FDAby the to assessFDA to the assess individual the individual Why is Why it important is it important that the that test the be test be clearedcleared by the byFDA? the FDA? risk of breastrisk of cancer breast metastasis.cancer metastasis. As a truly As “next a truly generation” “next generation” diagnostic diagnostic test, MammaPrint test, MammaPrint Why is Why it important is it important that the that test the be test be MammaPrinttakesMammaPrint advantagetakes is theadvantage ofonly is the the gene progress ofonly theexpression gene progress made expression pro leby made the cleared Humanpro leby the clearedbyHumanGenome the FDA byGenome Project the to assessFDA andProject to the recentassess andindividual advances therecent individual advances riskin of multigene breastriskin of multigenecancer breast microarray metastasis.cancer microarray technologymetastasis. As technologya truly toAs analyze“next a truly to generation” analyze“nextthe complex generation” the diagnostic complex biology diagnostic biology oftest, a tumor MammaPrint oftest, a and tumor MammaPrint and Since you Since and you yourcleared and doctor yourcleared by willdoctor the be by FDA? makingwill the be FDA? makinglife decisions life decisions takesprovide advantagetakes provideyou advantage and of youthe your progressand of clinician the your progress made clinician with bydetailed made thewith Human bydetailed information the HumanGenome information about Genome Project your about andProject cancer yourrecent and1-3 cancer. advances recent1-3. advances about yourabout treatment your treatment based on based the resultson the of results the test, of the you test, you in multigenein multigene microarray microarray technology technology to analyze to analyzethe complex the complex biology biologyof a tumor of a and tumor and Sincecannot you Since underestimatecannot and you your underestimate and doctor your the willdoctorimportance bethe making willimportance be of makinglifethe decisionsreview of lifethe anddecisionsreview and provide provideyou and you your and clinician your clinician with detailed with detailed information information about your about cancer your1-3 cancer. 1-3. aboutapproval youraboutapproval treatmentby your a regulatory treatmentby baseda regulatory body. on based the MammaPrint body. resultson the MammaPrintof results the being test, of the you being test, you cannotcleared underestimatecannot clearedas In underestimateVitro as InDiagnostic the Vitro importance Diagnostic the Multivariate importance of Multivariate the Indexreview of the Assay andIndexreview Assay and How does How SYMPHONY does SYMPHONY genomic genomic tests differ tests from differ genetic from genetic testing? testing? approval(IVDMIA)approval by(IVDMIA) aby regulatory the by Unitedaby regulatory the body. StatesUnited MammaPrint body.Food States andMammaPrint Food Drug being and Drug being clearedAdministration clearedas AdministrationIn Vitro as providesInDiagnostic Vitro providesDiagnostic con dence Multivariate con dence Multivariate in its Index safety in Assayits Indexand safety Assay and (IVDMIA)(IVDMIA) by the Unitedby the StatesUnited Food States and Food Drug and Drug HowGenetic does HowGenetic testing SYMPHONY does referstesting SYMPHONY to refers the genomic study to the genomic of study testsgenes ofdiffer and testsgenes their from differ and role theirgenetic fromin inheritance; role genetic testing?in inheritance; howtesting? certain how certain effectiveness.effectiveness. The FDA The label FDA states label that, states as that,a diagnostic as a diagnostic tool, tool, AdministrationAdministration provides provides con dence con dence in its safety in its and safety and traits or traitsconditions or conditions are passed are frompassed one from generation one generation to the next, to the such next, as suchBRCA. as BRCA. MammaPrintMammaPrint has 98.9% has reproducibility98.9% reproducibility for classifying for classifying GeneticGeneticGenetic testingGenetic tests referstestingassess tests tothe refersassess the likelihood study tothe the likelihoodof study ofgenes your of and ofgettinggenes your their and gettingcancer. role their in cancer.inheritance; role in inheritance; how certain how certain effectiveness.patientseffectiveness.patients as “Low The asFDA Risk” “Low The label or FDA Risk” “Highstates label or that,Risk”. “Highstates as that,Risk”.a diagnostic as a diagnostic tool, tool, traits or traitsconditions or conditions are passed are frompassed one from generation one generation to the next, to the such next, as suchBRCA. as BRCA. MammaPrintMammaPrint has 98.9% has reproducibility98.9% reproducibility for classifying for classifying GeneticOn theGenetic tests Onother assessthe testshand, other the assess genomic likelihoodhand, the genomic likelihoodtests of yourstudy tests ofgetting the yourstudy genes gettingcancer. the of genes a cancer.tumor of a once tumor you once already you alreadyhave havepatients MammaPrintpatients asMammaPrint “Low asis Risk” the“Low onlyor is Risk” the“High gene onlyor Risk”.expression “High gene Risk”.expression test for testbreast for breast cancer. cancer. Genomic Genomic tests look tests at thelook behavior at the behavior of the tumor of the to tumor predict to predictits response. its response. cancer currentlycancer currently available available in the United in the StatedUnited thatStated has that has On the Onother the hand, other genomic hand, genomic tests study tests the study genes the of genes a tumor of a once tumor you once already you alreadyhave have MammaPrintmet theMammaPrintmet stringent is the the stringent only criteria is the gene only forcriteria expression IVDMIA gene for expression IVDMIA clearance test for clearance testbreast by FDAfor breast 3by. FDA 3. cancer.SYMPHONY cancer. GenomicSYMPHONY is Genomic a tests suite islook ofa tests suitegenomic at thelook of behaviorgenomic at tests the analyzingbehavior oftests the analyzing tumor ofa pro lethe to tumor a predictof pro le over to predictits1300of response.over genes its1300 response. genes cancer currentlycancer currently available available in the United in the StatedUnited thatStated has that has involvedinvolved in the activity in the activityof a speci c of a speci cbreast cancer breast tumor.cancer tumor.It provides It provides a genomic a genomic met“The the clearancemet stringent“The the clearance of thestringent criteria MammaPrint of the forcriteria MammaPrint IVDMIA test for marks IVDMIA clearance test a step marks clearanceforward bya step FDA in forward the3by. effortFDA in the 3to. joineffort molecular to join molecular medicine medicinewith with SYMPHONYsignatureSYMPHONYsignature ofis athe suite complex ofis of athe suitegenomic complex biology of genomic tests biologyof youranalyzing tests oftumor youranalyzing a pro leto tumor assess a of pro leto theover assess risk 1300of theofover the genesrisk 1300 cancer of the genes cancer current medicalcurrent care. medical MammaPrint care. MammaPrint results will results provide will patients provide andpatients their andcaregivers their caregivers with more with information more information involvedcominginvolved in comingback the activity andin back the helps activity ofand a determine speci chelps of a determine speci cbreast the speci c cancer breast the speci ctreatment tumor.cancer treatmenttumor.It providesthat YOU It providesthat a need. genomic YOU a need. genomic “The aboutclearance“The the aboutclearance ofprospects the the MammaPrint ofprospects for the disease MammaPrint for test outcome. disease marks test outcome. a Thisstep marks information forward a Thisstep informationin forward the will effort serve in the willtoas joinefforta serve backup molecular toas join ato backup makingmolecular medicine to decisions making medicinewith decisions with signaturesignature of the complex of the complex biology biologyof your oftumor your to tumor assess to the assess risk theof the risk cancer of the cancer current medicalcurrent care. medical MammaPrint care. MammaPrint results willabout results provide treatment.” willabout patients provide treatment.” (FDA) andpatients their (FDA) andcaregivers their caregivers with more with information more information coming comingback and back helps and determine helps determine the speci c the speci ctreatment treatment that YOU that need. YOU need. about the-Dr.about prospectsAndrew the-Dr. C. prospects Andrewfor von disease Eschenbach, C. for von outcome. disease Eschenbach, M.D., outcome. This Former M.D.,information CommissionerThis Former information will Commissioner serve of U.S. willas aFood serve backupof U.S.and as aFoodDrugto backup making andAdministration Drugto decisions making Administration decisions about treatment.”about treatment.” (FDA) (FDA) -Dr. Andrew-Dr. C. Andrew von Eschenbach, C. von Eschenbach, M.D., Former M.D., Commissioner Former Commissioner of U.S. Food of U.S.and FoodDrug andAdministration Drug Administration 5 5 6 6

5 5 6 6 How MammaPrint How MammaPrint was validated? was validated?

5 5 6 6 WhatWhat should should I do Ito do have to have the SYMPHONYthe SYMPHONY breast breast cancer cancer BluePrintBluePrint investigates investigates 80 genes 80 genes that identifythat identify the molecular the molecular subtype subtype of your of your genomicgenomic pro le pro le ordered ordered for me? for me? tumortumor so that so youthat and you yourand yourdoctor doctor can choose can choose the drug the drugcombination combination that offersthat offers the bestthe therapeuticbest therapeutic result result for your for yourspeci c speci c tumor tumor type. type. There There are four are mainfour main DuringDuring your yourpreliminary preliminary consultation, consultation, ask your ask yourdoctor doctor to order to order subtypes:subtypes: HER2 HER2 (also (alsocalled called ERBB2), ERBB2), basal, basal, luminal luminal A and A luminaland luminal B. Each B. Eachof these of these the SYMPHONYthe SYMPHONY suite suiteof tests of testsso that so youthat can you make can make more more molecularmolecular subtypes subtypes respond respond differently differently to various to various therapies. therapies. By knowing By knowing your your informedinformed decisions decisions about about treatment treatment options options for you. for you. subtype,subtype, your yourdoctor doctor can select can select the most the mosteffective effective treatment treatment for your for yourtype oftype of cancer.cancer.

7 7

4 4 WhatWhat is the is theSYMPHONY SYMPHONY personalized personalized WillWill my myinsurance insurance cover cover the thecost cost of SYMPHONY? of SYMPHONY? breastbreast cancer cancer Pro le? Pro le? AgendiaAgendia bills billsinsurance insurance companies companies on behalf on behalf of insured of insured patients patients throughout throughout the Unitedthe United The TheSYMPHONY SYMPHONY personalized personalized genomic genomic pro le pro le for breast for breast States.States. Based Based on the on patient’sthe patient’s speci c speci c bene t bene t level, level, the insurancethe insurance companies companies may maypay apay a portion or all of the cost of the Symphony tests. cancercancer began began as one as onetest, test,MammaPrint MammaPrint®. It® . It portion or all of the cost of the Symphony tests. nownow includes includes 4 tests, 4 tests, MammaPrint, MammaPrint, BluePrint BluePrintTM, TM, TargetPrintTargetPrint®, and®, andTheraPrint TheraPrint®. Each®. Each of these of these tests tests WhatWhat if I don’tif I don’t have have insurance insurance or my or myinsurance insurance doesn’t doesn’t cover cover it? it? lookslooks at different at different gene gene sets setsin your in your tumor tumor and andprovides provides in-depthin-depth information information about about speci c speci c tumor tumor AgendiaAgendia is a compassionateis a compassionate company company offering offering a wide a wide range range of nancial of nancial assistance assistance characteristics.characteristics. Your Your tumor tumor characteristics characteristics will helpwill help programs.programs. Please Please contact contact Agendia’s Agendia’s billing billing department department at 888-363-7868 at 888-363-7868 or or [email protected]@agendia.com. directdirect your your personal personal treatment treatment plan. plan.

3 3 8 8 Personalized Medicine:

The SYMPHONY genomic pro le will guide your treatment decisions and help answer the following questions:

9 2 No two tumors are alike….

TIME Magazine chose MammaPrint as one of the “Five Best Healthcare Inventions of the Year” naming it “Cancer’s Crystal Ball.”

10 10 1 1 AdvantagesAdvantages of SYMPHONY of SYMPHONY breast breast cancer cancer pro le: pro le:

M-USA-002-V1